An updated research of glycogen synthase kinase-3β inhibitors: a review
Monatshefte fur Chemie, ISSN: 0026-9247, Vol: 152, Issue: 1, Page: 19-33
2021
- 4Citations
- 12Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
Abstract: Glycogen synthase kinase-3β (GSK-3β) is a highly conserved multifunctional serine/threonine (Ser/Thr) protein kinase widely expressed in many tissues. GSK-3β inhibitors could be used in the treatment of human key diseases, such as cancer, Alzheimer’s disease, Parkinson’s disease, inflammation, type-II diabetes, and so on, due to the multi-role of GSK-3β in the hepatic glycolysis regulation, cell signaling pathways, and phosphorylation of various proteins. Recently, sets of diverse GSK-3β inhibitors have been prepared, and biologically evaluated in vitro and in vivo in different screening models. This review summarizes the latest developments in GSK-3β inhibitors unclosed from 2015 to 2019, including their structure–activity relationship and bioactivity studies. Graphic abstract: [Figure not available: see fulltext.]
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know